Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $16.44 million versus the consensus estimate of $15.85 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• Putin is said to skip G20 with Tump in U.S., attend APEC in China - Bloomberg
• Strategy (MSTR) call put ratio 2.3 calls to 1 put as share price up 8.3%